Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Prostate cancer updates: TITAN and ENZAMET

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 3514

Prof Ian Davis and Prof Axel Merseburger

Professor Axel Merseburger and Professor Ian Davis discuss the latest data from the TITAN trial and ENZAMET trial presented at ASCO 2019 in Chicago, commenting on key efficacy and safety data and the distinguishing features of each trial. The experts also reflect on the ARCHES study presented at ASCO GU 2019 and the anticipated impact these trials will have on the clinical landscape.

Latest data from the TITAN trial
Key findings from the ENZAMET trial
Potential treatment combinations for patients with prostate cancer
Overview of the ARCHES trial

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation